Nhwa Pharmaceutical receives approval for class 1 chemical drug trial

Jiangsu Nhwa Pharmaceutical (SZSE:002262) announced it has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA) for its Class 1 chemical drug, NH104 tablets. The approval covers two specifications of NH104 tablets, 5 mg and 20 mg. NH104 is a new generation innovative drug for the treatment of insomnia and depression with insomnia. The company expects to begin clinical trials shortly. According to the company, NH104 is derived from internal independent research, and the company exclusively owns its intellectual property rights. The company will proceed with clinical trials as required by the NMPA.